Clinical Trials
6 trialsNCT06324240 2026-01-26
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
Phase 1 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04132817 2022-12-02
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
Bristol-Myers Squibb
Phase 1 Completed
NCT01986426 2018-10-03
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
Phase 1 Completed
NCT01502592 2016-01-05
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00060372 2013-03-27
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
National Cancer Institute (NCI)
Phase 1 Completed